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COVID-19 has had a detrimental impact on access to hip and knee arthroplasty surgery. We set out 
to examine whether this had a subsequent impact on pre-operative opioid prescribing rates for 
those awaiting surgery. 
Materials and Methods:  
Data regarding patient demographics and opioid utilisation were collected from the electronic 
health records of included patients at a large university teaching hospital. Patients on the outpatient 
waiting list for primary hip and knee arthroplasty as of September 2020 (COVID-19 group) were 
compared with historical controls (Controls) who had previously undergone surgery. A sample size 
calculation indicated 452 patients were required to detect a 15% difference in opioid prescription 
rates between groups. 
Results: 
A total of 548 patients (58.2% female) were included, 260 in the COVID-19 group, and 288 in the 
Controls.  Baseline demographics were similar between the groups. For those with data available, 
the proportion of patients on any opioid at follow up in COVID-19 group was significantly higher: 
55.0% (143/260), compared with 41.2% (112/272) in the Controls (p=0.002). This remained 
significant when adjusted for confounding (age, gender, Scottish Index of Multiple Deprivation, 
procedure and wait time). The proportion of patients on a strong opioid was similar (4.2% [11/260] 
versus 4.8% [13/272]) for COVID-19 and Controls respectively. The median waiting time from referral 
to follow up was significantly longer in the COVID-19 group compared with the Controls (455 days vs 
367 days; p<0.0001). 
Conclusion: 
The work provides evidence of potential for an emerging opioid problem associated with the 
influence of COVID-19 on elective arthroplasty services. Viable alternatives to opioid analgesia for 
those with end-stage arthritis should be explored, and prolonged waiting times for surgery ought to 





Hospitals worldwide were forced to restructure when the Coronavirus (COVID-19) pandemic called 
for an immediate significant shift towards prioritisation of acute care1. This led to widespread 
postponement of elective orthopaedic procedures in concordance with the need for resource 
reallocation, as well as concerns over risk of nosocomial infection transmission and the impact of 
COVID-19 on surgical risk2.  
Whilst these changes have served to “flatten the curve” and reduce some of the harm associated 
with COVID-19 infection, there has undoubtedly been an impact on patients whose elective 
procedures were postponed. Patients awaiting hip and knee arthroplasty, as one of the most 
common elective procedures, have been disproportionally affected 3. It has been estimated that 
over 6 million elective orthopaedic procedures were cancelled worldwide during the first peak of the 
pandemic 4. With continued delays in the provision of timely total hip and knee arthroplasty 
expected for some time due to the considerable backlog of patients awaiting surgery, patients will 
need to seek alternative treatment options to manage their symptoms.  
Opioids are often used as a last line for symptomatic pain management in end-stage osteoarthritis5. 
However, there is increasing evidence for limited benefit6 and long-term detriment to health 7, 
especially in older adults 8. More specifically within the arthroplasty population long-term opioid use 
pre-operatively has been associated with increased risk of peri-operative complications 9, 10 , poorer 
functional outcome 11, 12, and ongoing opioid dependence post-operatively 13, 14.  
Increased risk of opioid harm has been identified in unscheduled care clinical settings associated 
with the COVID-19 pandemic 15, 16, but it is currently not understood how the associated increase in 
waiting times for surgery has influenced routine pre-operative opioid prescribing for patients 
awaiting elective operations.  
 We have therefore set out to address this important clinical question through a comparative study 
of opioid utilisation pre-surgery in a historical cohort versus patients on the waiting list for primary 
hip and knee arthroplasty whose surgery has been delayed secondary to COVID-19. 
 With evidence that surgical delay associated with the COVID-19 pandemic has led to a deterioration 
in arthritis severity, associated pain and reduced quality of life 17, we hypothesise that this will be 
associated with increasing use of opioid analgesia within the population awaiting surgery to manage 
this exacerbation of symptoms pre-operatively.  
 
Methods  
Study design, setting and participants 
We undertook a retrospective cohort study of patients awaiting primary hip and knee arthroplasty at 
a large university teaching hospital in Scotland. Using a theatre management system (Centricity 
Opera, GE Healthcare, Chalfont St Giles, United Kingdom) two groups were identified, those on the 
outpatient waiting list for surgery (as of September 2020) who had their operation delayed due to 
COVID (COVID-19 group), and a historical comparison of patients that had previously been on the 
outpatient waiting list and had been operatively managed between 2016 and 2017 (Controls). 
Patients in the COVID-19 group had been added to the waiting list between May 2019 and April 
2020, whereas patients in the Controls were added between December 2014 and August 2017. The 
timeframe for the Controls was chosen due to feasibility of data access and availability. Previous 
analysis of unpublished data had not identified a temporal trend in incidence regarding opioid 
prescription for arthroplasty patients prior to the COVID-19 pandemic (Supplementary Table 1). 
Exclusion criteria included: patients undergoing other types of arthroplasty operation (for example 
unicompartmental arthroplasty, revision arthroplasty, or arthroplasty at other anatomical sites), 
patients in the Controls who did not undergo operative management, and patients in the COVID-19 
group that had been added then removed from the waiting list as of September 2020 (start of data 
collection period). No patient in the COVID-19 group had yet undergone surgery at the time when 
data collection was performed (September 2020 – October 2020). 
Standard practice at the study centre pre-COVID was that patients would be referred from general 
practice and then reviewed by orthopaedic surgeons to determine their eligibility for arthroplasty 
surgery. Patients would then be added to the waiting list for surgery if eligible. A further pre-
assessment clinic review was then performed 2-4 weeks prior to surgery. The timeframe from date 
of referral from general practice to orthopaedic review was typically 3-6 months. The timeline from 
addition to the waiting list to date of surgery was usually about a further 3-9 months dependent on 
individual surgeon waiting list length. 
Data collection 
A preformatted data collection proforma was utilised for data extraction. Data was obtained from 
the patient electronic health record, which included patient demographic data, waiting list details, 
clinical letters (including referral details), linked Primary Care prescribing records (Scottish national 
Prescribing Information System) and pre-assessment documentation (where applicable). 
Variables included in the data collection proforma were: 
Demographic: Age, gender, Scottish Index of Multiple Deprivation (SIMD) 
Pharmacological: On opioid at referral, on opioid at follow up, type of opioid (strong 
[morphine/diamorphine/fentanyl/oxycodone/buprenorphine/hydromorphone/tapendadol/methad
one]  vs weak [codeine/dihydrocodeine/tramadol]), as defined in the British National Formulary 18). 
All combination productions containing any of the above-described medications were also classified 
as opioids. 
Process of care: Date of referral, date of follow-up (pre-surgery), time from referral to follow up 
Medical: history of anxiety or depression, site of operation (hip vs knee) 
Sample size calculation 
An a-priori sample size calculation was performed utilising a freely available online tool 19. A sample 
size calculation indicated a minimum of 452 patients were required to detect a 15% difference in 
opioid prescription between groups at p<0.05 and 90% power with a baseline expected outcome 
proportion of 50% in the Controls. The expected proportion of opioid prescription in the controls 
was extracted from the unpublished data outlined in Supplementary Table 1, where a mean 
proportion of 55% for any opioids was observed between 2012-2017. A slightly lower value was 
chosen to avoid overestimation given the opioid prescription proportion was lower in the latter half 
of this study period. 
Statistical analysis 
Initial data scoping was performed to identify the presence and type of missing data extracted. 
Missing data was present in <0.5% fields with no evidence of missing data not at random therefore a 
decision was made that no formal data imputation techniques were required. Pairwise deletion was 
utilised to manage missing data fields, with no patient excluded due to missing data. 
Baseline assessment of covariates was then performed using a Student t-test for normally 
distributed continuous data, a Mann-Whitney U test for non-normally distributed continuous data, 
and a Chi-squared test for categorical data.  
Comparisons between waiting time from referral to follow up was also performed. For patients in 
the COVID-19 group this was the date of referral from the general practitioner to the time of 
individual patient data collection (September to October 2021). For patients in the Controls this was 
the date of referral from the general practitioner up to the date of surgery. Waiting times were 
identified as non-normally distributed from a Shapiro-Wilk test and therefore a Mann-Whitney U 
test was performed. 
Finally, comparative analysis between the number of patients on an opioid at referral and at follow-
up was performed using a Chi-squared analysis. Multivariable logistic regression was used to assess 
the potential impact of pre-identified confounders (age, gender, SIMD, procedure, history of anxiety 
& depression and wait time) on the results. 
All statistical analyses were performed using SPSS for Windows (version 24.0, SPSS Inc.). In all 
analyses p<0.05 denoted statistical significance. 
Ethics 
Our study was conducted in accordance with the 1964 Helsinki declaration and its later 
amendments. Given the nature of the study as a retrospective review of anonymised patient data, 
ethical approval was not required. Data storage and analysis was undertaken in alignment with the 
Caldicott principles – the data guardianship regulations governing the use of patient data in the 
United Kingdom. There was no external funding source for the study. The study has been reported 




Patients Demographics  
A total of 548 patients (58.2% female) was included in our study, 260 in the COVID-19 group, and 
288 in the Controls.  Of those individuals 295 were listed for primary hip arthroplasty (53.8%), and 
253 primary knee arthroplasty (46.2%). The mean age was 69 years (range 22-95). The median SIMD 
was 7 [Interquartile range (IQR) 5-9} (indicating lower than average deprivation compared with 
national levels). 121 out of 548 patients (22.0%) presented with a previous diagnosis of anxiety/ 
depression or both. 
The characteristics of studied patients are summarised in Table 1.  Overall, both groups shared 
similar demographics characteristics, although there was a weak association for higher anxiety and 
depression in the Controls (p=0.05). 
Table 1: Comparisons of demographics of COVID-19 and Controls groups. TKR: Total Knee 
Replacement; THR: Total Hip Replacement; SIMD: Scottish Index of Multiple Deprivation; IQR: 
Interquartile Range. Table created by authors 
 COVID-19 (n=260) Controls (n=288) P value 
 
Median Waiting Time 
There was a significant increase in the waiting time of patients being referred until pre-surgical 
follow up. Median time for follow-up from referral in the COVID-19 group was 455 days (IQR 368-
626) versus 365 (IQR 238-519) days in the Controls, a 90-day difference (p<0.001).  
Change in Opioid Use 
Table 2 illustrates the volume of opioids used by patients in COVID-19 group and Controls at referral 
and at follow up. Formal statistical comparisons of the differences between weak and strong opioid 
groups were not performed due to low absolute numbers. The proportion of patients on a strong 


























SIMD, median 7 (IQR 6-9) 7 (IQR 5-9) 0.77 
History of 
anxiety/depression  
48 (18.4%) 73 (25.3%) 0.05 
 COVID-19 (n=260) Controls (n=288) P value 
Percentage of patients 
on opioid at referral 






38.6% [32-44] (98/254) 
2.0% [0-4] (5/254) 
40.6% [35-47] (103/254) 
 
 
49.8% [44-56] (143/287) 
2.8% [1-5] (8/287) 






Table 2: Difference in opioid utilisation between the COVID-19 and Controls at referral and at follow-
up. Table created by authors. The denominator for numbers (n) of patients included at each stage 
reflect data availability for each specific sub-group. 
 
At referral, the percentage of patients on any opioid in the COVID-19 group was 12 percentage 
points lower than in the Controls (40.6% vs 52.6% respectively, p=0.005). This remained significant 
when adjusted for potential confounding (age, gender, SIMD, procedure, history of anxiety and 
depression and wait time) (Supplementary Table 2). 
However, at follow up, the COVID-19 group demonstrated an upward trend in any opioid use while 
the Controls showed a downward trend (Table 2). Final percentages of opioid utilisation at follow-up 
were 13.8 percentage points higher in the COVID-19 group vs the Controls (55.0% vs 41.2% 
respectively, p=0.002). This again remained significant when adjusted for potential confounding 
(Supplementary Table 3).  
 
Discussion  
This study suggests a marked negative impact of the COVID-19 pandemic on patients awaiting joint 
replacement in relation to delay to surgery and opioid use. We identified that patients were required 
to wait longer for their surgery (88-day difference in median wait time from referral to follow-up), 
and a significantly larger proportion of patients were prescribed opioid based analgesia (14 
percentage points more in the COVID-19 group compared with our historical Controls) pre-
operatively, despite a lower frequency of opioid use at referral. Given the previously known 
associations between pre-operative opioid use and poorer peri-operative surgical outcomes 9-14, 
urgent attention is required to identify alternative effective non-operative treatment strategies or 
expedite operative intervention for those awaiting arthroplasty surgery. Increasing use of opioid 
medication routinely within this healthcare setting may also have larger long-term consequences for 
public health 20.  
Percentage of patients 
on opioid at follow-up 






50.8% [45-57] (132/260) 
4.2% [2-7] (11/260) 
55.0% [49-61] (143/260) 
 
 
36.4% [31-42] (99/272) 
4.8% [2-7] (13/272) 






The justification for the increasing use of opioid analgesia in those awaiting arthroplasty surgery is 
limited, although this may be related to the lack of strong evidence for other pharmacological 
solutions for arthritic pain, and/or a response to difficulties in alleviation of patient suffering. There 
is however some evidence that non-steroidal anti-inflammatory medication (NSAIDs) provide at least 
similar analgesic efficacy to opioids for osteoarthritis and have a better safety profile, particularly 
when considering topical formulations 21. Intra-articular injections are another alternative, with 
some evidence for short term pain relief from corticosteroid injection 22, hyaluronic acid 23, protein-
rich plasma 24 and saline 25. There are however concerns about the potential risks for side effects 
with these treatments, including deterioration in arthritis severity 26, and post-operative infection 27, 
that limit their use peri-operatively.  
Non-pharmacological interventions such as physiotherapy 28, 29, use of offloading braces in the knee 
setting 30, and neurological ablation therapy 31 have also been identified as having a potential role to 
improve symptoms in end-stage osteoarthritis. High-quality evidence for benefit is however lacking, 
although the side-effect profile from such interventions is likely to different than any 
pharmacological alternatives. 
Given the lack of viable alternative to joint replacement surgery it is imperative that the recent 
significant increase in the waiting list is addressed 32. There is substantial evidence available for the 
mental, physical and economic negative impact of extended surgical waiting times in arthroplasty 
patients, in both the short and long term 33-37. A recent paper by Scott et al. 17 has shown that a 
significant proportion of those patients awaiting hip and knee arthroplasty are now classified, 
according to their self-reported EuroQOL-5d scores, as in a health state “worse than death”; with the 
vast majority reporting symptom deterioration associated with surgical delays secondary to the 
COVID-19 pandemic. Whilst restarting elective services has to be taken in the context of overall 
hospital workflow, there is evidence for the relative safety of undertaking arthroplasty procedures 
with appropriate protocols in place 38, and that the majority of patients wish to proceed with surgery 
in view of the relative benefit and risk involved 39. Given the vast backlog of patients awaiting 
surgery accumulated secondary to the pandemic it will likely take several years of increased activity 
before a return to normality is realised. This once again therefore highlights the importance of 
reducing where possible the pre-operative opioid prescribing for these patients as evidenced by our 
research.  
The strengths of our study include broadly similar cohorts from before and during the pandemic. We 
also provide adjustment for known confounders to attempt to ensure the associations seen are a 
true reflection of clinical practice. The results provided likely represent an underestimate of true 
effect given that the proportion of patients on an opioid at referral was significantly higher in the 
Controls, and also the fact that no patients in the COVID-19 group had yet undergone surgery, 
indicating the potential for further individuals to be started on opioids associated with ongoing 
delays. 
 It is however possible that the analysis is skewed by unadjusted confounders and accuracy of clinical 
information recorded within the electronic health record, as well as the possible interference of the 
COVID-19 pandemic on psychological and social lives of patients. Historical data collection sources 
however retained accuracy due to electronic records’ lack of susceptibility to recall bias. Use of a 
historical cohort may also add potential bias within treatment and group effects, although no 
previous temporal trends were identified in the supplementary data. No data was available 
regarding timing of opioid prescription in relation to waiting time which could have helped better 
define any temporal trends in a relationship between surgical delay and opioid use. It should also be 
noted that data from the COVID-19 group was truncated (as the patients had not yet undergone 
surgery) and therefore these results are an underestimate of the actual difference in median waiting 
time. We were also unable to examine the doses and strengths of medication prescribed to and 
consumed by patients to provide a more nuanced reflection on opioid consumption.  
Overall, we feel that the sample provides a realistic reflection of current practice that is likely 
applicable to similar healthcare systems, particularly given that disruption to elective orthopaedic 
services was a widespread occurrence at a national level during the pandemic. It however must be 
emphasised that due to the nature of the study design no causality can be determined in the 
relation to the associations identified between increasing opioid use and the COVID-19 pandemic. 
Further analyses utilising larger scale national data samples consisting of surgical and prescribing 
data will be of use to confirm the associations seen here and provide additional insights into the 




Despite a suggested reduction in opioid use at referral, COVID-19 has been associated with a higher 
proportion of patients prescribed opioids that has potential to invoke short- and long-term patient 
harm. Viable alternatives to opioid prescription for those awaiting surgery must be urgently 
identified, with a widespread public health message to prescribers about the negative consequences 
of long-term opioid prescribing in arthroplasty patients. Prolonged waiting times for surgery should 
be avoided in in the recovery from COVID-19 to prevent more widespread opioid use in this 
population, particularly in sight of the documented lack of clinical efficacy, large side effect profiles, 
and potential for long term opioid dependence. 
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